Skin Tingling and Burning on a GLP-1 Microdose: Dysesthesia, Allodynia, and What the Dose Data Shows
Burning or tingling skin on a GLP-1 has a medical name, dysesthesia, and the FDA label for Wegovy says it becomes more common as the dose rises. No trial has measured it at sub-label microdoses, so the best evidence comes from studying the other end of the dose range.
22.9%
REPORTED DYSESTHESIA ON SEMAGLUTIDE 7.2 MG IN STEP UP
6.0%
REPORTED DYSESTHESIA ON SEMAGLUTIDE 2.4 MG IN STEP UP
3 to 93
DAYS FROM FIRST INJECTION TO SYMPTOMS IN FRENCH CASE REPORTS
It tends to get described in odd, specific ways. A t-shirt seam feels wrong, the back feels sunburned with no sun, or a light touch on the thigh stings. Nothing shows on the skin, and the symptom often sounds too strange to mention at an appointment.
This article covers what the symptom is, how strongly it tracks dose, what the labels say about recovery, and which signs point to something else. Nearly all of the numbers come from doses far above a microdose. We flag that wherever it limits what you can conclude.
Key takeaways
- •In the STEP UP trial, dysesthesia affected 22.9% of adults on semaglutide 7.2 mg, 6.0% on 2.4 mg and 0.5% on placebo.
- •The Wegovy label states that dysesthesia incidence increased with dosage and with drug levels in the blood.
- •We found no trial reporting dysesthesia at sub-label microdoses, although individual reports include onset at semaglutide 0.75 mg.
- •The Zepbound label lists dysesthesia at 0.2% to 0.4% across tirzepatide 5 mg to 15 mg, against 0.1% on placebo.
- •Of 38 Wegovy patients who recovered and returned to 7.2 mg, 17 (45%) reported dysesthesia again.
What does GLP-1 dysesthesia feel like?
GLP-1 dysesthesia usually feels like burning, tingling or tenderness in skin that looks normal. A review by Labib and colleagues (Journal of the American Academy of Dermatology, 2023) defines dysesthesia as an abnormal skin sensation with no unusual stimulus and no primary skin disorder. Allodynia is the related term for pain from something that should not hurt, such as clothing or a light touch.
Laroche and colleagues give the most detailed clinical picture so far (European Journal of Clinical Pharmacology, 2026). They found 4,281 dysesthesia reports among 426,945 GLP-1 reports in the WHO VigiBase database, or 1.0%. In 15 detailed French cases, burning mostly affected the back, abdomen, thighs and arms, while tingling mostly affected the hands and feet.
Terms used in 4,281 GLP-1 dysesthesia reports (% of reports)
Laroche ML et al., Eur J Clin Pharmacol 2026, VigiBase. Voluntary reports with no denominator, so these are not rates of occurrence. Five most relevant terms shown.
Reports like these need careful reading. Of the VigiBase reports, 79.5% were classed as non-serious, 70.6% came from consumers, and 69.2% involved women. That last figure may reflect who takes these medicines and who reports symptoms, so it does not establish that women are at higher risk. Pain at the spot where you inject is usually a separate issue, covered in our guide to injection site reactions.
Does a higher GLP-1 dose make skin burning more likely?
Yes, for semaglutide, and the pattern is strong. The current Wegovy label (revised June 2026) says incidence "increased with increasing dosage and drug levels in the blood." Two randomized trials published in The Lancet Diabetes & Endocrinology in 2025 show it clearly: STEP UP (Wharton and colleagues) in 1407 adults without diabetes, and STEP UP T2D (Lingvay and colleagues) in 512 adults with type 2 diabetes.
Participants reporting dysesthesia, by weekly semaglutide dose (%)
Wharton S et al. (STEP UP) and Lingvay I et al. (STEP UP T2D), Lancet Diabetes Endocrinol 2025. Separate randomized trials, both funded by Novo Nordisk.
- Without diabetes
- With type 2 diabetes
A separate phase 2 trial by Aroda and colleagues (Diabetes Care, 2025) tested doses up to 16 mg for 40 weeks in 245 people with type 2 diabetes. Its 2 mg arm reported no cases at all, and the placebo arm reported more. Of 19 cases in 17 participants, 11 were mild and 8 were moderate.
Participants reporting dysesthesia in a high-dose trial (%)
Aroda VR et al., Diabetes Care 2025. Phase 2 trial. Small arms, so the difference between 0% and 2% should not be overread.
Can you get skin burning on a GLP-1 microdose?
Possibly, but the actual rate at a microdose is unknown. We found no trial that reports dysesthesia at sub-label doses of semaglutide or tirzepatide. Wegovy starts at 0.25 mg a week and reaches a maintenance dose of 1.7 mg or 2.4 mg, and Zepbound starts at 2.5 mg, yet neither label breaks out dysesthesia during those early weeks.
The dose pattern suggests lower risk at lower doses, and that is the most anyone can honestly say. It does not mean zero. Among the French pharmacovigilance cases, one woman developed burning across her thighs, buttocks and back at semaglutide 0.75 mg, and a man developed it at 1.0 mg. A paraesthesia case involved dulaglutide 0.75 mg. Those reports show that it can happen, and they cannot tell us how often.
One published patient offers a useful illustration, with all the limits of a single case. Described by Laroche and colleagues, he stopped semaglutide 2 mg because of whole-body burning, then restarted at 0.25 mg with slow increases. He tolerated 1 mg well, and milder burning returned when he went back to 2 mg. A threshold may exist for some people, though no study has tested where it sits.
Does skin burning happen with tirzepatide, retatrutide or oral GLP-1s?
Yes, the symptom has been recorded across the class, at very different rates. Semaglutide tablets show it too, which suggests the injection itself is not the cause. Aroda and colleagues made the same point, writing that route of administration does not appear to determine it.
Altered skin sensation on semaglutide, by form (%)
Wegovy label, revised 6/2026 (injection and tablets); OASIS 1 (50 mg daily) as summarized by Laroche ML et al., 2026. Separate trials, not a head-to-head comparison. The injection's 2% is the label's pooled figure from its 2.4 mg weight-reduction table. STEP UP recorded 6.0% on the same dose, so rates vary by trial. Oral and injected mg doses are not equivalent.
- Semaglutide
- Placebo
The Zepbound label (revised August 2026) reports low tirzepatide rates. Retatrutide, which is still investigational, ran higher in TRIUMPH-2 (Bellido and colleagues, The Lancet, 2026), a trial of 1152 adults with obesity and type 2 diabetes. Our article on whether microdosing retatrutide is safe explains why its low doses are a separate question.
Dysesthesia with tirzepatide and retatrutide (%)
Zepbound label, pool of Study 1 and 2; Bellido V et al., Lancet 2026 (TRIUMPH-2). Different trials, populations and event definitions, so drugs cannot be ranked from this chart.
- Drug
- Placebo
Other evidence fits a dose pattern across drugs. Orforglipron reached 1.2% at 36 mg against 0.6% on placebo in ATTAIN-1, as summarized by Laroche and colleagues. Reports to the European database by Popa Ilie and colleagues (Pharmaceuticals, 2026) found a dysesthesia signal for semaglutide when compared with tirzepatide, though publicity and reporting habits can shape that kind of signal. Case reports by Chakrabarti and colleagues (American Journal of Case Reports, 2026) describe moderate-to-severe allodynia in 2 tirzepatide patients, tied to dose escalation.
When does GLP-1 skin burning start, and how long does it last?
It tends to start around a dose increase, and it usually fades, though the timeline varies widely. In the French cases, symptoms began 3 to 93 days after the first injection, with onset during dose escalation. A systematic review of 101 studies by Gupta and colleagues (Medical Sciences, 2026) also found events frequently occurring during escalation.
Duration in published cases ranges from days to months. A woman described by Ahern (Cureus, 2025) felt sunburned for about six weeks on semaglutide 2.4 mg before it cleared without any change. In a series of 4 people by Stark and colleagues (American Journal of Health-System Pharmacy, 2025), the 2 who stopped improved, and one of the 2 who continued recovered after 4 months.
What happened to 288 patients with dysesthesia on Wegovy 7.2 mg (%)
Wegovy label, section 6.1, revised 6/2026. The label reports each category separately. This is the highest approved dose, so these figures do not describe a microdose.
The label adds two details worth knowing. Events resolved faster when action was taken on the drug, and most who did not recover during the trial had kept the same dose. Recurrence is also common: of 38 patients returned to 7.2 mg after recovering, 17 (45%) reported it again. All 3 French rechallenge cases recurred at the same dose. Those observations were not randomized, so they cannot prove what a dose change does.
What causes burning skin on a GLP-1?
Nobody knows yet. The leading idea is a direct effect on nerves, because sensory neurons carry both GLP-1 and GIP receptors, according to a review by de Sousa and colleagues (Diabetes, 2025). That is a plausible mechanism and has not been demonstrated as the cause.
Weight loss and nutrient depletion seem less likely to explain the typical case. Laroche and colleagues point out that in STEP UP the rise came shortly after the jump from 2.4 mg to 7.2 mg, too soon for fat loss to account for it. They add that B-vitamin and copper deficiency tend to cause slowly progressive neuropathy, which fits poorly with short onset and quick recovery. Taking a supplement is therefore not an established fix, although our guide to micronutrients on a microdose covers why intake still matters in general.
What should you do if your skin burns or tingles on a GLP-1?
Tell your prescriber, and check your dose before assuming anything else. We found no trial testing a treatment for this symptom, so creams, supplements and nerve medicines remain unproven here. Laroche and colleagues suggest tailoring management to how much it affects quality of life, since trial participants often improved while continuing and some real-world patients stopped.
Dose accuracy deserves a real look on a microdose. One man described by Quarenghi and colleagues (JACEP Open, 2026) accidentally took a total of 9.6 mg through a pen handling error and developed generalized burning, which resolved within 7 days. Our guide to storage and dosing accuracy goes through how measuring errors happen. A short note of the following can help your prescriber:
- •The date it began, and the date of your last dose change
- •Where on the body you feel it, and whether it matches a nerve or skin change you can see
- •Whether it rises and falls with the injection day
- •Any history of neuropathy, diabetes, or new medicines
Burning skin also has causes unrelated to your medicine. Labib and colleagues link generalized dysesthesia with infection, autoimmune disorders, neuropathies and malignancy, which is why a new symptom deserves a proper assessment. Some presentations cannot wait for a routine appointment:
- •Call emergency services for swelling of the face, lips or throat, trouble breathing, sudden weakness, sudden confusion or vision change, or blistering with a widespread rash or sores in the mouth or eyes. Gupta and colleagues list angioedema, hypersensitivity and severe skin reactions as uncommon events with these medicines.
- •Seek same-day care for gradually spreading numbness, limb weakness or severe pain. Zahir and colleagues (BMC Neurology, 2025) describe a woman with progressive leg numbness and weakness, blurred vision and thiamine deficiency after rapid weight loss on a GLP-1. Bagheri and colleagues (Cureus, 2026) report burning, stabbing pain after blood sugar improved markedly on tirzepatide, where treatment-induced neuropathy could not be definitively established.
Skin burning on a GLP-1 is a recognized side effect that tracks dose at the higher end of the range. Its rate at a microdose is unmeasured, so a new symptom on a low dose is worth raising with a prescriber, and no reason to adjust a dose alone.
Frequently asked questions
Why does my skin burn or tingle on a GLP-1?
Burning or tingling on a GLP-1 is called dysesthesia, an abnormal skin sensation without a visible skin disorder. The FDA label for Wegovy lists it as a side effect and says it became more common as dose and blood levels rose. The mechanism is unknown. Sensory neurons do carry GLP-1 and GIP receptors, which is one line of investigation.
Does a GLP-1 microdose cause skin burning?
Nobody has measured this directly, because we found no trial reporting dysesthesia at sub-label microdoses. Rates climbed steeply with dose at the upper end, which suggests lower doses may carry less risk, but that is an inference. Spontaneous reports include onset at 0.75 mg of semaglutide, so a low dose does not rule it out.
How long does GLP-1 skin sensitivity last?
The duration varies, and there is no reliable average for low doses. Published cases describe a sunburned feeling lasting about six weeks and allodynia clearing after 4 months on continued treatment. On Wegovy 7.2 mg, 18% of those affected had not reported recovery by the end of the trial, mostly people whose dose stayed unchanged.
Does tirzepatide cause skin burning too?
Tirzepatide can, but the labeled rate is low. The Zepbound label reports dysesthesia at 0.2% on 5 mg, 0.2% on 10 mg and 0.4% on 15 mg, against 0.1% on placebo. Case reports describe allodynia during dose escalation that resolved after stopping. Direct rate comparisons with semaglutide are shaky because the drugs were tested in separate trials.
Should I stop my GLP-1 if my skin hurts?
Call your prescriber before changing anything, unless you have symptoms that need urgent care. In the Wegovy 7.2 mg data, most people who reduced, paused or stopped recovered, and action on the dose was linked with faster resolution. Whether that applies to low doses is untested, and a prescriber can weigh how much the symptom affects daily life.
Will GLP-1 skin burning come back if I go back up in dose?
It may. On the Wegovy label, 38 patients who recovered were re-escalated to 7.2 mg, and 17 of them, or 45%, reported dysesthesia again. In three French pharmacovigilance cases with rechallenge, symptoms returned at the same dose. One published patient tolerated a slow return to 1 mg of semaglutide, then had milder burning again at 2 mg.
Is burning skin on a GLP-1 caused by a vitamin deficiency?
Probably not in the typical case, though a clinician may still check. Laroche and colleagues note that B-vitamin and copper deficiency cause chronic, slowly progressive neuropathy, which fits poorly with onset within 3 to 93 days and quick improvement after stopping. Severe deficiency has been reported in a GLP-1 user with leg numbness and weakness, so those symptoms need assessment.
When is numbness or skin pain on a GLP-1 urgent?
Call emergency services for swelling of the face, lips or throat, trouble breathing, sudden weakness, sudden confusion or vision change, or blistering with a widespread rash or sores in the mouth or eyes. Seek same-day care for gradually spreading numbness, limb weakness or severe pain. Those features are not the usual picture of mild dysesthesia. Case reports link GLP-1 use to rare neuropathy and thiamine deficiency, and a systematic review lists uncommon severe skin and hypersensitivity reactions.
Clinical references
- WEGOVY (semaglutide) injection and tablets. US prescribing information, revised 6/2026. DailyMed
- ZEPBOUND (tirzepatide) injection. US prescribing information, revised 8/2026. DailyMed
- OZEMPIC (semaglutide) injection. US prescribing information, revised 5/2026. DailyMed
- Wharton S, Freitas P, Hjelmesæth J, et al. Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. The Lancet Diabetes & Endocrinology. 2025. doi:10.1016/S2213-8587(25)00226-8
- Lingvay I, Bergenheim SJ, Buse JB, et al. Once-weekly semaglutide 7·2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial. The Lancet Diabetes & Endocrinology. 2025. doi:10.1016/S2213-8587(25)00225-6
- Aroda VR, Jørgensen NB, Kumar B, et al. High-Dose Semaglutide (Up to 16 mg) in People With Type 2 Diabetes and Overweight or Obesity: A Randomized, Placebo-Controlled, Phase 2 Trial. Diabetes Care. 2025. doi:10.2337/dc24-2425
- Bellido V, le Roux CW, Ekinci EI, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. The Lancet. 2026. doi:10.1016/S0140-6736(26)01861-1
- Laroche ML, Géniaux H, Jardou M. Dysesthesia associated with GLP-1 agonist therapies: data-mining analysis and literature review. European Journal of Clinical Pharmacology. 2026. doi:10.1007/s00228-026-04079-7
- Gupta AK, Teasell EM, Magalhães RF, et al. Cutaneous Adverse Events Associated with Semaglutide, Liraglutide and Tirzepatide: A Systematic Review. Medical Sciences. 2026. doi:10.3390/medsci14060652
- Popa Ilie IR, Ghibu S, Butuca A, et al. Incretin-Based Drugs for Obesity: Common and Drug-Specific Reporting Patterns of Adverse Drug Reactions. Pharmaceuticals. 2026. doi:10.3390/ph19060876
- Stark J, Klass MJ, Owen L. Allodynia (skin tenderness) associated with semaglutide: A case series. American Journal of Health-System Pharmacy. 2025. doi:10.1093/ajhp/zxaf008
- Chakrabarti MP, Han S, Campbell NM. Cutaneous Allodynia Associated With GLP-1RA Tirzepatide for Weight Management: A Case Series. The American Journal of Case Reports. 2026. doi:10.12659/AJCR.952158
- Ahern S. Allodynia and Dysesthesia Associated With Semaglutide and Tirzepatide. Cureus. 2025. doi:10.7759/cureus.94126
- Quarenghi M, Stanga A, Bergamaschi A, et al. Prolonged Dysesthesia After Massive Accidental Semaglutide Overdose: A Case Report. Journal of the American College of Emergency Physicians Open. 2026. doi:10.1016/j.acepjo.2026.100427
- de Sousa E, Sparks L, Townsend K. Incretin Receptors in the Peripheral Nervous System: Implications for Obesity Treatment and Peripheral Neuropathy. Diabetes. 2025. doi:10.2337/db25-0158
- Labib A, Burke O, Nichols A, et al. Approach to diagnosis, evaluation, and treatment of generalized and nonlocal dysesthesia: A review. Journal of the American Academy of Dermatology. 2023. doi:10.1016/j.jaad.2023.06.063
- Zahir A, Collins D, Ip S, et al. Neurological complications associated with rapid weight loss and nutritional deficiencies following GLP-1 agonist use: a case report. BMC Neurology. 2025. doi:10.1186/s12883-025-04540-7
- Bagheri K, Buck E, Muley S, et al. Treatment-Induced Neuropathy Presenting as Thoracic Radiculopathy and Abdominal Wall Protrusion After Marked Glycemic Improvement With Tirzepatide. Cureus. 2026. doi:10.7759/cureus.117153
Medical disclaimer. This article is for general educational and informational purposes only. It is not medical advice and not a substitute for a clinician who knows your history. Sub-label "microdose" regimens have not been tested for dysesthesia in clinical trials, and most figures here come from standard or high doses. Talk to your prescriber before starting, changing or stopping any medicine, and seek urgent care for severe or rapidly worsening symptoms. Charts show values reported in the cited sources.